174 A PHASE II RANDOMIZED CONTROLLED TRIAL OF POMX VS. PLACEBO PRIOR TO RADICAL PROSTATECTOMY
Stephen Freedland,Michael Carducci,Nils Kroeger,Alan Partin,Jian-yu Rao,Yusheng Jin,Susan Kerkoutian,Hong Wu,YunFeng Li,Patricia Creel,Kelly Mundy,Robin Gurganus,Helen Fedor,Serina King,David Heber,Yanjun Zhang,Allan Pantuck
DOI: https://doi.org/10.1016/j.juro.2012.02.225
2012-01-01
Abstract:You have accessJournal of UrologyProstate Cancer: Epidemiology and Natural History I1 Apr 2012174 A PHASE II RANDOMIZED CONTROLLED TRIAL OF POMX VS. PLACEBO PRIOR TO RADICAL PROSTATECTOMY Stephen Freedland, Michael Carducci, Nils Kroeger, Alan Partin, Jian-yu Rao, Yusheng Jin, Susan Kerkoutian, Hong Wu, YunFeng Li, Patricia Creel, Kelly Mundy, Robin Gurganus, Helen Fedor, Serina King, David Heber, Yanjun Zhang, and Allan Pantuck Stephen FreedlandStephen Freedland Durham, NC More articles by this author , Michael CarducciMichael Carducci Baltimore, MD More articles by this author , Nils KroegerNils Kroeger Los Angeles, CA More articles by this author , Alan PartinAlan Partin Baltimore, MD More articles by this author , Jian-yu RaoJian-yu Rao Los Angeles, CA More articles by this author , Yusheng JinYusheng Jin Los Angeles, CA More articles by this author , Susan KerkoutianSusan Kerkoutian Los Angeles, CA More articles by this author , Hong WuHong Wu Los Angeles, CA More articles by this author , YunFeng LiYunFeng Li Los Angeles, CA More articles by this author , Patricia CreelPatricia Creel Duke, NC More articles by this author , Kelly MundyKelly Mundy Durham, NC More articles by this author , Robin GurganusRobin Gurganus Baltimore, MD More articles by this author , Helen FedorHelen Fedor Baltimore, MD More articles by this author , Serina KingSerina King Baltimore, MD More articles by this author , David HeberDavid Heber Los Angeles, CA More articles by this author , Yanjun ZhangYanjun Zhang Los Angeles, CA More articles by this author , and Allan PantuckAllan Pantuck Los Angeles, CA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.225AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Pomegranate extract and juice slow prostate cancer (PC) xenograft growth. In a randomized trial of two doses of a standardized pomegranate extract (POMx, Pom Wonderful, Los Angeles, CA) in men with PSA recurrence after primary treatment, POMx lead to significantly longer PSA doubling times vs. pre-study, though no dose-effect was seen. The effects of POMx (or any pomegranate product) on human prostate tissue biology are unknown. The most prevalent DNA oxidation product in human cells is 8-hydroxy-2-deoxyguanosine (8-OHdG), a promutagenic base modification detectable in genomic DNA and a candidate biomarker for antioxidant status and cancer risk. As pomegranate extracts reduce oxidative stress in animals, we hypothesized POMx given prior to radical prostatectomy (RP) would lower tissue 8-OHdG levels. METHODS 70 men at two sites were randomized to 2 tablets of POMx daily or placebo for 4 wks prior to RP. At surgery, frozen and paraffin embedded prostate tissues were collected and analyzed for intra-prostatic pomegranate metabolite levels, for benign and malignant tissue 8-OHdGexpression, and for PC cell expression of pS6, NFkB, and Ki67. The study was powered to detect a 30% reduction in 8-OHdG levels. RESULTS POMx was well tolerated with no treatment-related withdrawals. There were no differences in baseline features between arms. The pomegranate metabolite Urolithin A was more often detected (p=0.031) and with higher levels in the POMx arm (p=0.007). In our primary end-point, we found 16% lower benign prostate tissue 8-OHdG in the POMx arm (p=0.095), that did not reach significance. Secondary analyses of men with organ-confined PC found 33% lower benign prostate tissue 8-OHdGin the POMx arm (p=0.003), which remained significant after Bonferroni correction. There was no arm difference in PC tissue pS6 kinase, NFKB, or Ki67 levels, baseline PSA or PSA changes during study. There was an inverse correlation between Urolithin A levels and 8-OHdG expression in benign and malignant prostate tissues, which was significant in PC tissue (r=−0.299, p=0.017). CONCLUSIONS This modest sized study, short-term trial of POMx prior to RP found pomegranate metabolites are absorbed and accumulate in prostate tissues. This was suggestively, but not significantly linked with reduced benign prostate oxidative DNA damage; in a subset of men with early stage PC, this was significant. Given the lower benign prostate 8-OHdG levels observed , further study of POMx to reduce oxidative DNA damage and perhaps prevent PC are warranted; however these preliminary findings require validation in larger studies. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187 Issue 4S April 2012 Page: e73 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.Metrics Author Information Stephen Freedland Durham, NC More articles by this author Michael Carducci Baltimore, MD More articles by this author Nils Kroeger Los Angeles, CA More articles by this author Alan Partin Baltimore, MD More articles by this author Jian-yu Rao Los Angeles, CA More articles by this author Yusheng Jin Los Angeles, CA More articles by this author Susan Kerkoutian Los Angeles, CA More articles by this author Hong Wu Los Angeles, CA More articles by this author YunFeng Li Los Angeles, CA More articles by this author Patricia Creel Duke, NC More articles by this author Kelly Mundy Durham, NC More articles by this author Robin Gurganus Baltimore, MD More articles by this author Helen Fedor Baltimore, MD More articles by this author Serina King Baltimore, MD More articles by this author David Heber Los Angeles, CA More articles by this author Yanjun Zhang Los Angeles, CA More articles by this author Allan Pantuck Los Angeles, CA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...